Mark Prioletti is listed as a director on 1 SEC Form D filing by 1 issuer in Sep 2020: GENEREX BIOTECHNOLOGY CORP (Miramar, FL — pharmaceuticals — 2020; $2M reported sold to 7 investors).
What this means One deal on file with the SEC, filed Sep 2020. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Andrew Ro (1 shared filing), Anthony Crisci (1 shared filing), Brian McGee (1 shared filing), Craig Eagle (1 shared filing), James Anderson (1 shared filing) and 6 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Mark. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — 1 court case matching the name listed in Key records below.
What this means 1 record came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 1 public filing for Mark Prioletti and found 7 differences, 2 worth asking the sponsor about: Regulator action naming a team member: Generex Biotechnology Corporation (Jan 27, 2023); Regulator action naming a team member: Generex Biotechnology Corporation (Sep 23, 2022); and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.